Chief Executive Officer
Rob Kelley has more than 25 years of leadership experience in the biotechnology industry and has served as the Company’s Chief Executive Officer since December 2021. Mr. Kelley joined Talis as the Chief Commercial Officer in September 2020. Before Talis, Mr. Kelley was Vice President, Sales and Commercial Development of Genalyte, Inc., a healthcare analytics and point-of-care diagnostics company. Prior to Genalyte, Mr. Kelley served as Vice President, Marketing of Cardiff Oncology, Inc., a publicly held liquid biopsy company (formerly Trovagene, Inc.). Earlier in his career Mr. Kelley held various positions of increasing responsibility with Illumina, a publicly held biotechnology company, including Global Sales Manager for clinical applications of Next-Generation Sequencing and Director, Market Development, New and Emerging Opportunities. Mr. Kelley received a B.S. in Biology from Duke University and an M.B.A. from the UCLA. Anderson School of Management.